Thatcher Heumann
@HeumannThatcher
Followers
175
Following
390
Media
3
Statuses
69
Joined January 2020
RT @LesinskiLab: Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models!….
pubmed.ncbi.nlm.nih.gov
These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant...
0
10
0
RT @GillSharlene: #ASCO25 @ASCO .4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍.👇my top picks fo….
0
38
0
RT @Erman_Akkus: 🟡Is Claudin 18.2 expressed in biliary tract cancers?.@ESMO_Open . ✅29.5% express.gallbladder: 62.5%, extrahepatic: 53.4%,….
0
28
0
RT @HEP_Journal: Original Article.Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An inter….
0
33
0
RT @FordePatrick: Expansive review of IO across solid tumours in collaboration with Dr. Wang and my old colleague and friend Dr. Lei Zheng,….
0
11
0
RT @ArndtVogel: 🔥off the press.Precision surgery for hepatocellular carcinoma.@LancetGastroHep .👉the field is movin….
0
26
0
RT @JCOPO_ASCO: Detecting Early Recurrence With Circulating Tumor DNA in.Stage I-III Biliary Tract Cancer After Curative Resection: https:/….
ascopubs.org
PURPOSEThis study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively...
0
3
0
Check out our recent review of contemporary & novel IO in HCC! Fantastic effort by VUMC resident and my mentee @ShabnamEghbali. Link below. @CathyEngMD @VUMCMedicineRes @VUMC_Cancer @drlauragoff .
mdpi.com
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and, with only 15–20% of HCC patients being suitable for potentially curative treatments, the vast majority of...
0
1
3
RT @Erman_Akkus: 📢Hepatopancreaticobiliary cancers- Oral abstracts #ESMOAsia24 @myESMO . 1⃣LBA1 - Multicenter phase II trial of lenvatinib….
0
19
0
RT @MarkYarchoan: @TheLancetOncol: Path response with neoadj immunotherapy associates with RFS in #HCC. ⏩Time for randomized neoadj trials….
0
8
0
RT @ArndtVogel: 🔥off the press.Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC.@JHEP_Reports .🔎🗺️RWD….
0
13
0
RT @ArndtVogel: Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC.#ESMO24.🔎IMbrave050.👉RFS 33.2 vs 36 mo, H….
0
86
0
RT @MarkYarchoan: Most impressive data from #CheckMate9DW (frontline nivo/ipi in #HCC) is the median duration of response: 30.4 months❗️Rea….
0
23
0
RT @duiliorocha_onc: Top 3 GI abstracts from #ASCO24:. CheckMate 9DW - Nivo + Ipi vs TKI (sorafenib or lenvatinib) as 1L therapy of HCC. N….
0
28
0
RT @MarkYarchoan: The P3 #CheckMate9DW study (1L ipilimumab + nivolumab) is positive! Data are particularly compelling considering control….
0
18
0
RT @mdmanishshah: Important NCI funded ETCTN study. Even negative data is informative! Congratulations @VUMCHemOnc @CathyEngMD #MedIQAS….
0
6
0
RT @MarkYarchoan: Ipi/nivo in 1L #HCC is positive! (CheckMate-9DW study). Excited to see the full data soon.
news.bms.com
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb...
0
24
0
RT @ArndtVogel: Endoscopic variceal ligation vs propranolol for prevention of oesophageal variceal bleeding in HCC.@Gut_BMJ ..
0
22
0
RT @ArndtVogel: 🔥TACE + durvalumab +/- bevacizumab in HCC #GI24.✅ EMERALD-1, 616 pts.👉 ORR: 41 vs 43 vs 29%.👉 mPFS: 15 vs 10 vs 8.2 mo.👉 mO….
0
42
0
RT @MarkYarchoan: IPI+NIVO after prior PD1/L1 in HCC?.➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4).➡️ORR 22% (7….
0
28
0